endogenous serum erythropoietin ≤ 500 mUnits/mL
2 drugsPredictive biomarker for patient selection in 5 indications
2
Approved Drugs
5
Indications
2
Companies
endogenous serum erythropoietin ≤ 500 mUnits/mL is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 5 indications including Anemia, Chronic Kidney Disease, Human Immunodeficiency Virus Infection. Explore the targeted therapies, indications, testing methods, and companies developing endogenous serum erythropoietin ≤ 500 mUnits/mL drugs below.
Search endogenous serum erythropoietin ≤ 500 mUnits/mL Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting endogenous serum erythropoietin ≤ 500 mUnits/mL
| Drug | Company | Therapeutic Area |
|---|---|---|
| EPOGEN/PROCRIT | Amgen | Infectious Disease |
| RETACRIT | Pfizer | Renal |
endogenous serum erythropoietin ≤ 500 mUnits/mL Indications
Anemia Chronic Kidney Disease Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Myelosuppression